Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Kancera

Kancera
PUBLIC STATUS
11-20 EMPLOYEES
KAN STOCK SYMBOL
1 INVESTMENTS
$0.06 SHARE PRICE (As of Friday Closing)
Description

Kancera AB is a biotechnology company that focuses on the development and sale of drug candidates that have the potential to cure or to stops the progression of cancer. Its activities are divided into Pharmaceutical Development and Industrial Research and Development.

Website
Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Stock Exchange
STO
Primary Office
  • Karolinska Institutet Science Park
  • Banvaktsv√§gen 22
  • 171 48 Solna
  • Sweden

+46 08-501 000 00
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Kancera’s full profile, request a free trial.

Kancera Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$0.05 - $0.19 $12M $0.06 -$0.02 476K 210M

Kancera Financials Summary

In Thousands,
USD
TTM
30-Sep-2019
FY 2018
31-Dec-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
Enterprise Value 14,782 14,653 29,813 34,197
Revenue 391 41 13 36
EBITDA (4,327) (5,217) (6,449) (2,478)
Net Income (4,351) (5,279) (6,575) (2,603)
Total Assets 3,712 5,066 6,257 8,019
Total Debt 0 73 482 314
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Kancera Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000 17-Feb-2011 000000000000000000 000.00 Drug Discovery 000000 0000 00.0
To view this company’s complete investment and acquisition history, request access »

Kancera Executive Team (1)

Name Title Board
Seat
Contact
Info
Thomas Olin Ph.D Founder, Chief Executive Officer & Board Member

Kancera Board Members (1)

Name Representing Role Since Contact
Info
000000 0000 00.0 Kancera Founder, Chief Executive Officer & Board Member 000 0000